Compare Robinhood Markets, Inc. (HOOD) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Incyte Corporation — how do they compare? Robinhood Markets, Inc. trades at $106.56 (market cap $89.13B), while Incyte Corporation trades at $117 (market cap $23.11B). The key difference: Robinhood Markets, Inc. is far larger — about 3.9× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| HOOD | INCY | |
|---|---|---|
Market Cap | $89.13B | $23.11B |
Sector | Technology | Health |
52-Week High | $152.46 | $118.52 |
52-Week Low | $65.16 | $67.38 |
Enterprise Value | $90.33B | $19.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood Markets (HOOD) trades at $106.36, up 6.4% over 24 hours, with technical indicators showing a bearish trend near resistance at $106. The company reported strong 2025 results with $4.47B revenue and $1.88B net income, though Q1 2026 EPS missed expectations. Recent news highlights expansion into blockchain infrastructure and institutional stake changes.
Outlook remains mixed: analyst consensus is bullish with a $118.07 price target, but risks include earnings volatility and competitive pressures. The stock's high P/E of 48.19 suggests premium valuation, requiring sustained growth to justify current levels amid bearish technical signals.
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
